Exicure announces publication of results from Phase 2 study of burixafor

Exicure (XCUR) announced the publication of results from a prior Phase 2 clinical study evaluating burixafor, a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The manuscript, titled “Burixafor, a CXCR4 Inhibitor with a Differentiated Kinetics Profile: Results of a Phase 2 Study for Rapid Cell Mobilization in Multiple Myeloma and Lymphoma Patients Undergoing Transplant,” reports results from a 12-participant, multi-center, open-label Phase 2 study evaluating burixafor in combination with granulocyte colony-stimulating factor in patients with multiple myeloma, non-Hodgkin’s lymphoma, and Hodgkin disease undergoing autologous stem cell transplantation. In the study, 11 of 12 participants met the primary endpoint of collecting greater than or equal to 5.0×10^6 CD34+ cells/kg within two leukapheresis sessions, with six participants achieving the target in a single session. Median time to neutrophil and platelet engraftment was 12 and 22 days, respectively. Burixafor was generally well tolerated, with only two treatment-related adverse events reported, both low grade.